Skip to main content

Table 4 Correlation between CD34 expression with clinicopathological features in prostate cancer

From: Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer

Patients and tumor characteristics n(%) CD34 χ2 P-value
≤26 >26
PSA level (ng/ml)
  < 10 19 (25.3) 14 (73.7) 5 (26.3) 7.465 0.024
 10 ~ 20 29 (38.7) 13 (44.8) 16 (55.2)   
  > 20 27 (36.0) 9 (33.3) 18 (66.7)   
Gleason score
  ≤ 6 14 (18.7) 11 (78.6) 3 (21.4) 9.731 0.008
 7 28 (37.3) 15 (53.6) 13 (46.4)   
 8 ~ 10 33 (44.0) 10 (48.0) 23 (69.7)   
T stage
 T1–2 33 (44.0) 24 (72.7) 9 (27.3) 14.436 0.000
 T3–4 42 (56.0) 12 (28.6) 30 (71.4)   
Lymph node metastasis
 N0 46 (61.3) 27 (58.7) 19 (41.3) 5.452 0.020
 N1 29 (38.7) 9 (31.0) 20 (69.0)   
Distant metastasis
 M0 43 (57.3) 28 (65.1) 15 (34.9) 11.829 0.001
 M1 32 (42.7) 8 (25) 24 (75.0)   
TNM stage
 Stage II 26 (34.7) 18 (69.2) 8 (30.8) 7.187 0.007
 Stage III ~ IV 49 (65.3) 18 (36.7) 31 (63.3)   
  1. PSA prostate specific antigen